SMi is proud to present the return of their 11th annual Pediatric Clinical Trials Conference, 20th – 21st March 2017, London.
Strengthening strategies in pediatric investigation plans remains paramount and with the EMA 10-year review of pediatric regulation a call has been made for greater guidance with the goal of increasing the number of safe pediatric therapeutics on the market.
Join us as we discuss current clinical trials, implementation, and pediatric drug development in a series of interactive conference sessions, roundtables and workshops led by leading industry experts. Gain information on methods to improve clinical recruitment, appreciate ethical issues and navigate regulations when planning and executing a pediatric clinical trial. We will be exploring the complexities of pediatric drug formulation and helping you determine clinical endpoints.
Benefits of attending:
• Review and discuss pediatric clinical trial Legislation in the EU and globally
• Explore the practical costs and safety considerations of conducting a pediatric clinical trial
• Review the challenges in pediatric drug development for oncology drugs and vaccines
• Optimize your approach to pediatric formulation to improve clinical success
• Evaluate approaches for recruitment and retention
CHAIRS FOR 2017:
Robb Kahn, Former, Senior Safety Science Leader, Global Paediatric Oncology Drug Development, Genentech/Roche
Philippe Auby, CEO & President, OEDC (Otsuka Europe Development & Commercialization), Otsuka Europe
KEYNOTE SPEAKERS INCLUDE:
Bianca McDade, Director Regulatory Affairs, GSK
Tom Willgoss, Senior Outcomes Research Scientist, Patient-Centered Outcomes Research, Roche
Karl- Heinz Huemer, Scientific Committee Member and Expert, EMA Austria
Hernando Patino, Paediatric Drug Development Lead, Johnson & Johnson
Deborah Lee, VP Clinical Development, Insys Therapeutics
EARLYBIRDS AVAILABLE
For further information please click here or get in touch with Ameenah Begum on +44 (0) 20 7827 6166 or email: abegum@smi-online.co.uk